Can a common drug slow brain tumors? new study investigates acetadote in GBM
NCT ID NCT07387666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test how Acetadote, a drug that affects cell damage, changes metabolism in people with newly diagnosed glioblastoma. Ten participants will receive Acetadote before surgery, and researchers will use MRI scans and tumor tissue analysis to measure metabolic changes. The goal is to understand if Acetadote can slow tumor growth, not to provide a cure or treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Glioblastoma * 2\. Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent * 3\. Age ≥18 years * 4\. KPS \> 70 * 5\. Adequate organ and marrow function as defined below: * \- Bilirubin ≤1.5 times upper limit of normal * \- AST and ALT ≤ 3 times ULN * \- Creatinine ≤ 1.5 x ULN and/or GFR ≤ 60 mL/min * -ANC ≥ 1000 cells/ul * \- Platelet ≥ 100,000/ul * \- Hemoglobin ≥ 9 g/dl * 6\. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * 6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * \- Has not undergone a hysterectomy or bilateral oophorectomy; or * \- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * 7\. Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * 1.Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment. * 2\. Subjects must have recovered from prior treatment-related toxicities to grade 2 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment). * 3\. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study. * 4\. Brain metastases * 5\. History of allergic or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Acetadote. * 6\. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements. * 7\. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can repeated MRI scans reveal how tumors respond to radiation?
- Can a RAGE inhibitor tame brain swelling after tumor surgery?
- Can oxygen therapy boost immunotherapy against brain cancer?
- A drop of tears might reveal brain tumor secrets
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?